NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
Clinical Trials
17 trialsNCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT01662804 2021-05-27
Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01704716 2020-10-23
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
St. Anna Kinderkrebsforschung
Phase 3 Recruiting
NCT00698009 2020-09-24
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01701479 2020-07-14
LTI
St. Anna Kinderkrebsforschung
Phase 1/2 Unknown
NCT02173093 2019-01-29
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
University of Virginia
Phase 1/2 Unknown
NCT01576692 2018-11-15
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02130869 2017-12-22
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02771743 2016-05-24
Response-based Treatment of High-risk Neuroblastoma
Samsung Medical Center
Phase 2 Unknown
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed
NCT01404702 2014-12-02
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
University of Alabama at Birmingham
Phase 1 Terminated
NCT00054405 2013-04-09
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00005576 2013-01-16
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002748 2011-10-04
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00186862 2008-06-03
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed